At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 429 enrolled
Drug / intervention
Short Ragweed Pollen Allergenic Extract +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy And Safety Trial Of Sublingual-Oral Immunotherapy (SLIT) In Adults With Allergic Rhinoconjunctivitis Caused By Ragweed Pollen
In Brief
A Phase 3 clinical trial evaluating Short Ragweed Pollen Allergenic Extract and Placebo for Allergy. Completed, enrolled 429 participants across 1 site.
Detailed Summary
The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergy
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedMay 2011
Primary CompletionNov 2011
Study CompletionApr 2012
TodayJul 2026
First PostedMay 12, 2011
Enrollment StartApr 1, 2011
Primary CompletionNov 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.1 years ago
Interventions
Short Ragweed Pollen Allergenic Extractbiological
Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
Placebobiological
Placebo: Glycero-COCAs sublingual